AN2 Therapeutics Plans Phase 1 Study of Hypophosphatasia Drug for Second Half of 2027

PUBT · 2d ago
AN2 Therapeutics Plans Phase 1 Study of Hypophosphatasia Drug for Second Half of 2027
  • AN2 Therapeutics selected AN2-504661, an oral ENPP1 inhibitor, as a development candidate for hypophosphatasia.
  • Reported preclinical findings showed efficacy in animal models, favorable drug properties and an encouraging safety profile.
  • A Phase 1 study is planned for the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611040700BIZWIRE_USPR_____20261104_BW412833) on November 04, 2026, and is solely responsible for the information contained therein.